1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Skin conditions
  5. Psoriasis

Adalimumab for the treatment of adults with psoriasis

Technology appraisal guidance [TA146] Published date: 25 June 2008

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Related NICE guidance
  • 8 Review of guidance
  • Appendix A: Appraisal Committee members and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
Download guidance (PDF)

Guidance

  • Next

7 Related NICE guidance

7 Related NICE guidance

  • Infliximab for the treatment of adults with psoriasis. NICE technology appraisal guidance 134 (2008).

  • Adalimumab for the treatment of psoriatic arthritis. NICE technology appraisal guidance 125 (2007). [Replaced by NICE technology appraisal guidance 199]

  • Etanercept and infliximab for the treatment of adults with psoriatic arthritis. NICE technology appraisal guidance 104 (2006). [Replaced by NICE technology appraisal guidance 199]

  • Etanercept and efalizumab for the treatment of adults with psoriasis. NICE technology appraisal guidance 103 (2006).

  • National Institute for Health and Care Excellence (NICE)

  • Next